Flare is lighting up a new therapeutic space with an entirely different approach to decipher the biology of transcription factors to develop small molecule medicines. Based on insights from the seminal work of their scientific founders, Flare’s team is leveraging the power of ‘switch sites’ as druggable regions that hold the control for predictable and profound changes in DNA transcription, and therefore, gene expression. Flare’s drug discovery to target ‘switch sites’ has rapidly advanced, resulting in its pipeline of drug programs that address well-validated transcription factors, initially focused on precision oncology.